The new drug ‘Vyxeos’ that was introduced to Korea by Handok Pharmaceuticals may now be prescribed at general hospitals in Korea,

According to industry sources, Vyxeos (daunorubicin+ cytarabine), a treatment for adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), has passed the drug committees (DCs) meetings of several medical institutions in Korea including the National Cancer Center, Samsung Medical Center, Seoul National University Hospital, and Asan Medical Center, and Sinchon Severance Hospital.

However, Vyxeos is yet to be reimbursed in Korea. Its reimbursement agenda had been deliberated by the Natio